Literature DB >> 29573516

Reagent substitutions in the Centers for Disease Control and Prevention Nijmegen-Bethesda assay for factor VIII inhibitors.

C H Miller1, A B Payne1, J Driggers1, D Ellingsen1, B Boylan1, C J Bean1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29573516      PMCID： PMC6072586          DOI： 10.1111/hae.13434

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  10 in total

1.  The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.

Authors:  B Verbruggen; A Giles; J Samis; K Verbeek; E Mensink; I Novákovà
Journal:  Thromb Haemost       Date:  2001-12       Impact factor: 5.249

2.  A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay.

Authors:  Bert Verbruggen; Waander van Heerde; Irena Novákovà; David Lillicrap; Alan Giles
Journal:  Thromb Haemost       Date:  2002-08       Impact factor: 5.249

3.  Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.

Authors:  Geoffrey W Kershaw; Lin S Chen; Dayani Jayakodi; Scott M Dunkley
Journal:  Thromb Res       Date:  2013-09-21       Impact factor: 3.944

4.  Definitions in hemophilia: communication from the SSC of the ISTH.

Authors:  V S Blanchette; N S Key; L R Ljung; M J Manco-Johnson; H M van den Berg; A Srivastava
Journal:  J Thromb Haemost       Date:  2014-09-03       Impact factor: 5.824

5.  Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.

Authors:  C H Miller; S J Platt; A S Rice; F Kelly; J M Soucie
Journal:  J Thromb Haemost       Date:  2012-06       Impact factor: 5.824

6.  The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability.

Authors:  B Verbruggen; I Novakova; H Wessels; J Boezeman; M van den Berg; E Mauser-Bunschoten
Journal:  Thromb Haemost       Date:  1995-02       Impact factor: 5.249

7.  Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.

Authors:  C H Miller; B Boylan; A D Shapiro; S R Lentz; B M Wicklund
Journal:  J Thromb Haemost       Date:  2017-09-14       Impact factor: 5.824

8.  Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?

Authors:  C Pouplard; C Desconclois; F Sobas; M F Aillaud; C Ternisien; C Caron
Journal:  Int J Lab Hematol       Date:  2014-05-12       Impact factor: 2.877

9.  Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.

Authors:  Shawn F J Whelan; Christoph J Hofbauer; Frank M Horling; Peter Allacher; Martin J Wolfsegger; Johannes Oldenburg; Christoph Male; Jerzy Windyga; Andreas Tiede; Hans Peter Schwarz; Friedrich Scheiflinger; Birgit M Reipert
Journal:  Blood       Date:  2012-12-12       Impact factor: 22.113

10.  Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience.

Authors:  Ellinor I B Peerschke; Donna D Castellone; Marlies Ledford-Kraemer; Elizabeth M Van Cott; Piet Meijer
Journal:  Am J Clin Pathol       Date:  2009-04       Impact factor: 2.493
  10 in total
  3 in total

1.  Reagent substitution in the chromogenic Bethesda assay for factor VIII inhibitors.

Authors:  Amanda B Payne; Connie H Miller; Dorothy Ellingsen; Jennifer Driggers; Brian Boylan; Christopher J Bean
Journal:  Haemophilia       Date:  2019-07-29       Impact factor: 4.287

Review 2.  Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Authors:  C H Miller
Journal:  Haemophilia       Date:  2018-02-15       Impact factor: 4.287

Review 3.  Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.

Authors:  Richard A Marlar; Karin Strandberg; Midori Shima; Dorothy M Adcock
Journal:  Eur J Haematol       Date:  2019-11-13       Impact factor: 2.997
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.